KaloBios Pharmaceuticals, Inc. [KBIO] To Ring The NASDAQ Stock Market Closing Bell

ADVISORY, March 11, 2013 (GLOBE NEWSWIRE) --

What:

KaloBios Pharmaceuticals, Inc. [KBIO], a biopharmaceutical company dedicated to improving the lives of seriously ill patients with difficult-to-treat diseases through a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs), will visit the NASDAQ MarketSite in Times Square. 

In honor of the occasion, David Pritchard, President & CEO, will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43 ^rd & Broadway – Broadcast Studio

When:

Tuesday, March 12, 2013 – 3:45 p.m. to 4:00 p.m. ET   

Contact :

Joan E. Kureczka Kureczka/Martin Associates Tel: [phone] Mobile:  [phone] [e-mail]

Consuelo Alatorre KaloBios Pharmaceuticals, Inc. Tel: [phone] Mobile: [phone] [e-mail]

NASDAQ MarketSite:

Jen Knapp [phone] [e-mail]

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/NASDAQ .        

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaqomx .

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx .

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.                           

About KaloBios Pharmaceuticals, Inc. [KBIO]:

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.

1 2 3 Next › Last »